PFIZER

The big New York pharmaceutical company booked declining revenue in its two biggest operations.

AstraZeneca's board said the offer "substantially undervalues" the company and the method was not an acceptable deal pitch.

Pfizer said it proposed a takeover to AstraZeneca in January worth 58.8 billion pounds ($98.9 billion), or nearly 47 pounds per share.

The acquisition would be the biggest-ever foreign takeover of a British company and one of the largest-ever pharmaceuticals deals.

The deal's goal is to bolster best lines and exit weaker ones, as the sector contends with health care spending cuts and generic competition.

A deal could benefit Pfizer as it seeks to build up its cancer franchise, and acquiring AstraZeneca could bring cost savings.

After the closing bell, shares of Google Inc., Expedia Inc. and Gigamon Inc. were among Monday's biggest stock movers.

New York and New Jersey have had a rash of cases of medical fraud, which some say reflects a growing national trend.

The earnings calendar is a busy one while data on durable goods orders, and indexes on housing and consumer sentiment, are also awaited.

Water vapor exuded by e-cigarette users will expose a bystander to nicotine, but not carbon monoxide and other harmful compounds, a study finds.

Investors prepare for yet another earnings-heavy day with Wednesday’s FOMC meeting playing on their minds.

A board advised against using Xalkori, a lung cancer treatment, in the British National Health Service.

Lawsuits buy big pharma more time in India, but it's the drug development divisions that will ultimately lose out.

India revoked a patent on the breast cancer drug Tykerb, claiming it wasn't innovative enough to warrant protections.

However, the largest U.S. drugmaker's adjusted income fell 10% to $4 billion, or 56 cents per share.

The pharma giant aims to combat generic-drugmaker competition by restructuring and focusing on drugs for humans.

The move puts Amgen in the lead to buy the cancer-drug maker.

Onyx, a California-based cancer drug company, could soon be batting away buyout offers, as pharma majors prepare for a bidding war.

Israel generic drug producer Teva will pay Pfizer $1.6 billion in a new patent dispute settlement announced Wednesday.

The insider trading trial of Mathew Martoma, a former hedge fund portfolio manager for SAC Capital Advisors, is set for November.

Illinois' Hospira, which produces generic drugs, is being investigated by the FDA for violations at its Indian facility.